Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Up 92.6% in October

Virax Biolabs Group Limited (NASDAQ:VRAX) saw a large growth in short interest in October. As of October 31st, there was short interest totalling 446,500 shares, a growth of 92.6% from the October 15th total of 231,800 shares. Approximately 11.0% of the company’s shares are sold short. Based on an average daily trading volume, of 6,030,000 shares, the days-to-cover ratio is currently 0.1 days.

Virax Biolabs Group Price Performance

VRAX stock traded down $0.04 during mid-day trading on Thursday, reaching $1.90. The company had a trading volume of 86,276 shares, compared to its average volume of 2,230,932. The firm has a 50 day moving average of $2.19 and a 200 day moving average of $1.86. Virax Biolabs Group has a 12 month low of $0.60 and a 12 month high of $9.00.

About Virax Biolabs Group

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.